Citizens Initiates Coverage of Immix Biopharma (IMMX) with Market Outperform Recommendation

AAPL TSLA AMZN META AMD NVDA PEP COST ADBE GOOG AMGN HON INTC INTU NFLX ADP SBUX MRNA AAPL TSLA AMZN META AMD NVDA PEP COST ADBE GOOG AMGN HON INTC INTU NFLX ADP SBUX MRNA AAPL TSLA AMZN META AMD NVDA PEP COST ADBE GOOG AMGN HON INTC INTU NFLX ADP SBUX MRNA Stocks IMMX Citizens Initiates Coverage of Immix Biopharma (IMMX) with Market Outperform Recommendation March 09, 2026 — 08:04 pm EDT Written by George Maybach for Fintel-> Fintel reports that on March 9, 2026, Citizens initiated coverage of Immix Biopharma (NasdaqCM:IMMX) with a Market Outperform recommendation.

Analyst Price Forecast Suggests 30.83% Upside As of February 25, 2026, the average one-year price target for Immix Biopharma is $13.26/share. The forecasts range from a low of $12.12 to a high of $14.70. The average price target represents an increase of 30.83% from its latest reported closing price of $10.14 / share. See our leaderboard of companies with the largest price target upside. The projected annual revenue for Immix Biopharma is 12MM. The projected annual non-GAAP EPS is -0.87. What is the Fund Sentiment? There are 68 funds or institutions reporting positions in Immix Biopharma. This is an increase of 25 owner(s) or 58.14% in the last quarter. Average portfolio weight of all funds dedicated to IMMX is 0.13%, an increase of 347.49%. Total shares owned by institutions increased in the last three months by 710.97% to 24,393K shares. The put/call ratio of IMMX is 0.31, indicating a bullish outlook. What are Other Shareholders Doing?

Janus Henderson Group holds 3,922K shares representing 7.44% ownership of the company. Saturn V Capital Management holds 2,999K shares representing 5.69% ownership of the company.

Eventide Asset Management holds 2,549K shares representing 4.84% ownership of the company. Marshall Wace, Llp holds 1,979K shares representing 3.76% ownership of the company. In its prior filing, the firm reported owning 55K shares , representing an increase of 97.22%. The firm increased its portfolio allocation in IMMX by 7,975.60% over the last quarter. Millennium Management holds 1,660K shares representing 3.15% ownership of the company. In its prior filing, the firm reported owning 0K shares , representing an increase of 100.00%. Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.Click to Learn MoreThis story originally appeared on Fintel. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Tags Stocks Fintel Fintel is a leading provider of financial data and insights for intelligent, data-driven investors. With coverage of over 75,000 listed companies on all major stock exchanges, Fintel has the most comprehensive coverage of global equities at prices individual investors can afford. Check out our Unique Analysis of Insider Sentiment for Immix Biopharma, Inc.-> Find out what the Options Markets think of Immix Biopharma, Inc.-> See our take on Immix Biopharma, Inc. Upcoming Earnings-> More articles by this source-> Stocks mentioned IMMX More Related Articles This data feed is not available at this time. Data is currently not available • Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.